z-logo
open-access-imgOpen Access
Antimicrobial Properties of MX-2401, an Expanded-Spectrum Lipopeptide Active in the Presence of Lung Surfactant
Author(s) -
Dominique Dugourd,
Haiyan Yang,
Melissa Elliott,
Raymond Siu,
Jacob J. Clement,
Suzana K. Straus,
Robert E. W. Hancock,
Evelina Rubinchik
Publication year - 2011
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00322-11
Subject(s) - lipopeptide , pulmonary surfactant , antimicrobial , chemistry , microbiology and biotechnology , lung , medicine , biology , bacteria , biochemistry , genetics
MX-2401 is an expanded-spectrum lipopeptide antibiotic selective for Gram-positive bacteria that is a semisynthetic analog of the naturally occurring lipopeptide amphomycin. It was active againstEnterococcus spp., including vancomycin-sensitiveEnterococcus (VSE),vanA -,vanB -, andvanC -positive vancomycin-resistantEnterococcus (VRE), linezolid- and quinupristin-dalfopristin-resistant isolates (MIC90 of 4 μg/ml), methicillin-resistantStaphylococcus aureus (MRSA) and methicillin-sensitiveS. aureus (MSSA) (MIC90 of 2 μg/ml), coagulase-negative staphylococci, including methicillin-sensitiveStaphylococcus epidermidis (MSSE) and methicillin-resistantS. epidermidis (MRSE) (MIC90 of 2 μg/ml), andStreptococcus spp. including viridans group streptococci, and penicillin-resistant, penicillin-sensitive, penicillin-intermediate and macrolide-resistant isolates ofStreptococcus pneumoniae (MIC90 of 2 μg/ml). MX-2401 demonstrated a dose-dependent postantibiotic effect varying from 1.5 to 2.4 h. Furthermore, MX-2401 was rapidly bactericidal at 4 times the MIC againstS. aureus andEnterococcus faecalis , with more than 99.9% reduction in viable bacterial attained at 4 and 24 h, respectively. The MICs of MX-2401 against MRSA, MSSA, VSE, and VRE strains serially exposed for 15 passages to sub- to supra-MICs of MX-2401 remained within three dilutions of the original MIC. In contrast to that of the lipopeptide daptomycin, the antibacterial activity of MX-2401 was not affectedin vitro by the presence of lung surfactant, and MX-2401 was activein vivo in the bronchial-alveolar pneumonia mouse model, in which daptomycin failed to show any activity. Moreover, the activity of MX-2401 was not as strongly dependent on the Ca2+ concentration as is the activity of daptomycin. In conclusion, MX-2401 is a promising new-generation lipopeptide for the treatment of serious infections with Gram-positive bacteria, including hospital-acquired pneumonia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom